Combination Chemo‐Immunotherapy for Pancreatic Cancer Using the Immunogenic Effects of an Irinotecan Silicasome Nanocarrier Plus Anti‐PD‐1

There is an urgent need to develop new life‐prolonging therapy for pancreatic ductal adenocarcinoma (PDAC). It is demonstrated that improved irinotecan delivery by a lipid bilayer coated mesoporous silica nanoparticle, also known as a silicasome, can improve PDAC survival through a chemo‐immunothera...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Xiangsheng, Jiang, Jinhong, Liao, Yu‐Pei, Tang, Ivanna, Zheng, Emily, Qiu, Waveley, Lin, Matthew, Wang, Xiang, Ji, Ying, Mei, Kuo‐Ching, Liu, Qi, Chang, Chong Hyun, Wainberg, Zev A., Nel, Andre E., Meng, Huan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Full Papers
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7967046/
https://www.ncbi.nlm.nih.gov/pubmed/33747719
http://dx.doi.org/10.1002/advs.202002147

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7967046/
https://www.ncbi.nlm.nih.gov/pubmed/33747719
http://dx.doi.org/10.1002/advs.202002147

Ejemplares similares